Biogen reaches agreement with Samsung Biologics

By The Science Advisory Board staff writers

January 31, 2022 -- Biogen has reached an agreement with Samsung Biologics to sell an equity stake in the companies' biosimilar joint venture for up to $2.3 billion. Biogen and Samsung Biologics have built an anti-tumor necrosis factor portfolio in Europe.

Upon the acquisition of Biogen's stake, the companies will continue with their exclusive agreements, including the commercialization of their current portfolio. The portfolio includes benepali, imralditm, and flixabi (infliximab). Additionally, Biogen will retain commercial rights for byooviztm (ranibizumab-nuna) and SB15 (aflibercept).

Samsung Biologics has agreed to pay Biogen up to $2.3 billion for its stake in the joint venture. Biogen will receive $1 billion in cash at closing and $1.25 billion to be deferred over two payments. The first payment will comprise $812.5 million, which is due on the first anniversary of the transaction's closing. The second payment, $437.5 million, is due on the second anniversary. Biogen is eligible to receive up to $50 million, which is contingent on the achievement of certain commercial milestones.

Samsung Biologics reports Q4, 2021 fiscal year financial results
Samsung Biologics reported strong financial results for the fourth quarter and record high earnings for the 2021 fiscal year, achieving fourth quarter...
Samsung Biologics to join carbon neutral initiative
Contract development and manufacturing organization Samsung Biologics has signed a memorandum of understanding to join the Frontier 1.5D initiative, which...
AbbVie, Biogen, Pfizer release protein-coding genetic variants resource
A collaboration between AbbVie, Biogen, and Pfizer has created and recently launched a browsable resource that links rare protein-coding genetic variants...
Biogen, Ginkgo partner on enhanced AAV manufacturing for gene therapies
Biogen and Ginkgo Bioworks will collaborate to develop improved methods for manufacturing recombinant adeno-associated virus (AAV)-based vectors.

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter